Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial

James Chih‐Hsin Yang, Tibor Csőszi, Emmanuel de la Mora Jimenez et al.|Journal of Thoracic Oncology|2023

Cited by 55